2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 222

Serum Delta Neutrophil Index Measurement for Differentiating Acute Gouty Arthritis and Cellulitis in Normouricemic Patients

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 329

Serum Leptin and Risk of Knee Pain and Osteoarthritis: Multicenter Osteoarthritis Study

Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

9:00AM-11:00AM: Abstract Number: 753

Serum Levels of Tenascin-C Discriminate Patients with Active SLE from Inactive Patients and Healthy Controls, and Predict the Need to Escalate Immunosuppressive Therapy

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 607

Serum Progranulin (PRGN) Level Is Not a Biomarker for Responsiveness to Tumor Necrosis Factor (TNF)-Antagonist Therapy in Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 230

Serum Uric Acid As Short Term Mortality Predictor in the Acute Care Setting

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 121

Serum Uric Acid Levels and Gout Flares in a US Managed Care Setting

Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

9:00AM-11:00AM: Abstract Number: 9

Serum Visfatin Levels in Patients with Axial Spondyloarthitis and Early Rheumatoid Arthritis: Relation to Inflammation and Bone Changes

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 247

Severe Inflammation Following Vaccination Against Streptococcus Pneumoniae in Patients with Cryopyrin-Associated Periodic Syndromes

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 705

Sex Differences in Psoriatic Arthritis: Evaluation of a Real-Life Cohort of 2,118 Italian Patients Treated with Methotrexate

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 84

Sexual Dimorphism in the Association Between Multi-Site Pain and Other Fibromyalgia Features: an Analysis of Data from Three UK Population-Based Studies

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

9:00AM-11:00AM: Abstract Number: 274

Shrinking Lung Syndrome in Connective Tissue Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 646

Sicca Syndrome in Rheumatoid Arthritis: Is It a Real Sjögren’s?

Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 878

Significance of Interstitial Pneumonitis in Microscopic Polyangiitis

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 224

Silent Monosodium Urate Crystals Deposits in Asymptomatic Hyperuricemia Lead to a Higher Need for Coronary Revascularization

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 867

Simultaneous Measurement of 25-Hydroxyvitamin D and Procalcitonin in Granulomatosis with Polyangiitis (GPA): Differentiation of Activity from Infection?

Vasculitis Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].